Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750867 · ClinicalTrials.gov registry record · Phase 2
Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins
A Phase 2 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00750867 is a Phase 2 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 9 participants.
The verdict
NCT00750867, a Phase 2 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
Interventions
- DRUG intravenous immunoglobulin (IVIg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750867
The ClinicalTrials.gov registry entry for NCT00750867 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which intravenous immunoglobulin (IVIg) is the first listed.
NCT00750867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750867 about?
NCT00750867 is a clinical study titled "Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins". Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course...
What is the current status of trial NCT00750867?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00750867?
The interventions under investigation include: intravenous immunoglobulin (IVIg) (DRUG).
Who is sponsoring clinical trial NCT00750867?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.